MEI Pharma announced that, based on a count of the votes cast at the company’s Special Meeting of Stockholders, MEI, by a narrow margin, did not obtain the necessary stockholder votes to approve the merger agreement with Infinity Pharmaceuticals. The certified results show that 59.70% of outstanding shares were voted, of which 47.86% voted in favor of the proposed transaction, and 51.44% against. Accordingly, MEI has sent Infinity a notice terminating the merger agreement. “While we believe the benefits of the Infinity transaction were compelling for MEI stockholders, we appreciate and value the perspectives of our stockholders,” said David M. Urso, President and Chief Executive Officer of MEI Pharma. “Our Board and management team remain highly-focused on the potential for capturing the stockholder value inherent in the Company’s current development pipeline, which includes Voruciclib and ME-344. With clinical data expected from both of our clinical-stage pipeline programs around year-end and capital to support our near-term development plans, we are focused on the potential opportunities for creating stockholder value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MEIP:
- Anson, Cable Car respond to MEI Pharma’s attempt to prohibit director removal
- MEI Pharma responds to consent solicitation launched by Anson
- Anson, Cable Car file materials to remove entire MEI Pharma board
- MEI Pharma encourages shareholders to vote for Infinity transaction
- Infinity Pharmaceuticals reports stockholder approval of merger with MEI Pharma